6533b853fe1ef96bd12acc02

RESEARCH PRODUCT

Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats

Eberhard JähnchenW. Schmidt

subject

MaleTime Factorsmedicine.drug_classPharmaceutical ScienceIn Vitro TechniquesPharmacologyPhenprocoumonPharmacokineticsmedicineAnimalsPotencyDistribution (pharmacology)PharmacologyVolume of distributionChemistryAnticoagulantAnticoagulantsRats Inbred StrainsStereoisomerism4-HydroxycoumarinsBlood ProteinsRatsKineticsLiverPhenprocoumonStereoselectivityBlood Coagulation TestsEnantiomerProtein Bindingmedicine.drug

description

Abstract The elimination, distribution and anticoagulant activity of S(—)-, R(+)-, and R,S(±)-phenprocoumon were determined in male Wistar-Lewis rats after intravenous injection of a single dose of 0·6 mg kg−1. From the plasma concentrations which elicited the same anticoagulant effect, S(—)-phenprocoumon was 4 to 5 times more potent than R(+)-phenprocoumon. The potency of the racemate was between those of the enantiomers. The mean biologic half-life of the S(—)-enantiomer was shorter (12·5 h) than that of R(+)-phenprocoumon (17·8 h). No differences were observed in the apparent volume of distribution. However, the mean liver: plasma concentration ratio was higher for the S(—)-(6·9) than for the R(+)-enantiomer (5·2). At a total concentration of 16·8 μg ml−1 the percentage of unbound drug in rat serum was significantly higher for the S(—)- (1·13%) than that for the R(+)-enantiomer (0·76%). Values obtained for the racemate were always between those of the enantiomers. It is concluded that stereoselective differences in the distribution between plasma and liver, and consequently in the rate of elimination are most likely due to stereoselective differences in serum protein binding. The greater anticoagulant potency of the S(—)- over the R(+)-enantiomer, cannot be explained primarily by the observed pharmacokinetic differences.

https://doi.org/10.1111/j.2042-7158.1977.tb11309.x